F. Hoffmann-La Roche AG
Pharmaceuticals and DiagnosticsFounded 1896- Updated June 2025
Reviewed by Swet Parvadiya
Last reviewed: June 2025
CorpDigest
F. Hoffmann-La Roche AG
Financial Performance
Last reviewed: June 2025 · By Swet Parvadiya
Market Cap
$250.0B
Employees
101,000
CHF 59.4 billion in FY2024 revenue represents one of the largest pharmaceutical revenue bases in the world, generated by a company that operates with pharmaceutical gross margins consistently above 80 percent. The CHF 15.8 billion annual R&D investment — roughly 26 percent of revenue — is the financial commitment required to maintain a pipeline that can continuously replace drugs losing exclusivity to biosimilar competition. The diagnostics segment, approximately 25 percent of revenue, operates at margins below the pharmaceutical segment but provides a strategic value that financial statements do not capture directly: the diagnostic data that informs pharmaceutical R&D and identifies patient populations most likely to respond to specific drugs. A pharmaceutical trial that enrolls the right patients because of companion diagnostic stratification has materially higher success rates, which translates directly into reduced development cost and time for the pharmaceutical segment. The $250 billion market capitalization reflects investor confidence in the pipeline's ability to sustain revenue growth past the biosimilar competition period for legacy oncology biologics. Herceptin, Avastin, and MabThera — the drugs that drove Roche's oncology dominance for years — now face biosimilar competition in major markets, creating revenue pressure that the new generation of drugs must offset. The dual-class share structure at Roche, controlled by the Hoffmann and Oeri families, provides the long-term governance stability that supports the multi-decade R&D investment cycle. A company that spends CHF 15.8 billion annually on research needs a capital structure that insulates management from short-term earnings pressure; the family-controlled structure provides that insulation while maintaining public market liquidity through the non-voting bearer shares.
| Fiscal Year | Revenue | YoY Change |
|---|---|---|
| FY2024 | $66.5B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Roche reported full-year 2024 group sales of CHF 60.5 billion, up 7 percent at constant exchange rates and 3 percent reported, with Pharmaceuticals contributing CHF 45.7 billion (up 8 percent constant rate) and Diagnostics CHF 14.7 billion (up 4 percent constant rate). Core operating profit, the company's primary profitability metric excluding one-time charges and certain amortization, was approximately CHF 21.2 billion at a 35 percent core operating margin. Net income for the year was approximately CHF 9.2 billion, depressed by significant impairment charges including write-downs on certain pipeline assets and currency-translation effects. Free cash flow was approximately CHF 15 billion. The Swiss franc strength against the US dollar and euro reduced reported growth by several percentage points, a perennial issue for Roche given its CHF reporting currency and largely non-CHF revenue base. Major growth drivers in 2024 included Vabysmo, Hemlibra, Phesgo, and Ocrevus, while declines came from biosimilar erosion of legacy Avastin, Herceptin, and Rituxan franchises, and from COVID-19 test revenue normalization in Diagnostics. The company guided to mid-single-digit constant-rate sales growth and faster core EPS growth for 2025.
Roche Holding AG has an unusual capital structure with two listed instruments on the SIX Swiss Exchange. The Inhaberaktien (bearer shares, ticker ROG) carry one vote per share at the annual general meeting and represent the entirety of the voting power of the company. The Genussscheine (non-voting participation certificates, ticker ROG.GS, often referred to as Roche GS) carry no voting rights but participate equally in dividends and economic value. The Genussscheine trade in far larger volume than the bearer shares; daily volume in the GS is typically 100 to 200 times that of the bearer shares, which sit largely with the Hoffmann-Oeri family pool, Novartis (which has held a long-running roughly 33 percent bearer stake since 2001 to 2003), and a small public float. The structure means Roche can be acquired economically by investors who own the GS without giving up voting control to outsiders. The family pool together with Novartis has historically held a majority of bearer shares, but the relationships have become more arms-length over time. The GS line is what most international investors trade and what analysts price; the bearer share trades at a typical premium reflecting voting rights.
Roche has paid a dividend every year for decades and has increased the dividend every year for more than three decades, making it one of the longest dividend-growth records among large European companies. The 2024 dividend, paid in 2025, was CHF 9.70 per share, up from CHF 9.60 in 2023 and continuing an unbroken streak of annual increases that includes the 2008 financial crisis, the COVID-19 pandemic, and the Genentech buyout. The total cash distribution to shareholders for the 2024 financial year approached CHF 8 billion. Roche generally does not run a continuous share repurchase program; large repurchases have been used selectively, such as the CHF 19 billion buyback in 2020 from Novartis when Roche repurchased a one-third stake. The company's capital allocation framework prioritizes R&D investment of roughly CHF 13 billion per year, business development through acquisitions and licensing, debt service, and then the dividend. The conservative balance sheet, with net debt typically in the CHF 15 to 20 billion range against EBITDA of over CHF 24 billion, gives the company financial flexibility for opportunistic M&A while maintaining the dividend trajectory.
Roche invests approximately CHF 13 billion per year in research and development, roughly 22 percent of total group sales. The figure is among the largest absolute R&D budgets in pharmaceuticals and is exceeded in absolute dollars only by Johnson & Johnson, Merck & Co., and Pfizer in some years. On an R&D-intensity basis (R&D as a percentage of sales), Roche typically runs above the industry average of 18 to 20 percent. Roughly 80 percent of Roche's R&D spend goes to Pharmaceuticals and 20 percent to Diagnostics. The Pharma R&D budget is split across oncology (the largest single area), neuroscience, immunology, ophthalmology, hematology, and infectious diseases. The Diagnostics R&D budget supports the cobas instrument platforms, molecular diagnostics, and tissue diagnostics. Roche operates major R&D sites in Basel (Switzerland), South San Francisco (the Genentech headquarters retained as the Roche R&D hub for the US), Penzberg (Germany), and Shanghai. The R&D model emphasizes biologic medicines, where Roche has been a leader since the Genentech acquisition, alongside small molecules from the legacy Basel chemistry tradition. Productivity, measured as approved new molecular entities per dollar invested, has been a recurring strategic challenge for Roche and is one reason for the company's heavy acquisition activity.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "F. Hoffmann-La Roche AG Revenue & Financials." CorpDigest, https://corpdigest.com/company/roche/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>F. Hoffmann-La Roche AG reported $67B in revenue (FY2024).</strong><br>Source: <a href="https://corpdigest.com/company/roche/financials" target="_blank" rel="noopener">CorpDigest — F. Hoffmann-La Roche AG financials</a></div>